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Abstract 
Background: In practice, there is increasing recognition of the importance of hypothalamic pituitary adrenal axis in the 
cardiovascular disease progression. The association of brain natriuretic peptide with obesity and characteristics of the 
metabolic syndrome in adults and aged patients is well established, but that in pediatrics needs thorough elucidation.
Aim: The aim of this study was to assess the association of hypothalamic pituitary adrenal axis mediators (cortisol and 
aldosterone) with plasma NT-pro β-type natriuretic peptide (NT-proBNP) levels on metabolic, immune-inflammatory 
and endothelial markers in young obese pediatric patients.
Methods: This is achieved by recruitment of 60 young (13–17 years) obese pediatric cohorts who are further subclas-
sified according to their stage of hypertension; normotensive, prehypertensive and hypertensive patients.
Results: The study showed significant differences in the metabolic parameters (glucose, insulin and HOMA-index) 
among the three obese young patient groups. Levels of cortisol and aldosterone, as well as NT-proBNP levels are posi-
tively associated with characteristics of the metabolic syndrome; blood pressure, BMI, HOMA index in all three obese 
groups. However, their association to the lipid profile was insignificant. These increases aligned harmonically with 
the assessed immune-inflammatory markers; CRP, TNF-α, and IL-23, as well as levels of sICAM, sVCAM and p-selectin, 
reflecting the involvement of mast cells and inflammatory effects on the vascular endothelium. ROC analysis revealed 
their beneficial addition as promising biomarkers for a better prognostic profile of hypertension-induced cardiovascu-
lar risk.
Conclusion: Early detection of NT-proBNP, cortisol and aldosterone levels in pre-hypertension stage added to the 
immune-inflammatory mediators may improve the coronary risk assessment in young Egyptian patients.
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Background
Despite the high prevalence of hypertension in the adult 
population, identification of its key determinants remains 
arduous due to its multifaceted and polygenic nature. 
Because of to the striking epidemic state of childhood 
obesity, a growing number of obese adolescents are now 
at risk for this silent disease. Therefore, the medical rec-
ommendations are directed towards early detection of 
pre-hypertension (pre-HT) stages and actively targeting 
lifestyle patterns with various risk reduction measures in 
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serves as an early alarming manifest of certain metabolic 
derangements that will ultimately lead to metabolic syn-
drome (MS) and cardiovascular diseases. The association 
of obesity with the characteristics of the metabolic syn-
drome, and many other metabolic risk factors in adults 
and aged patients, is well established but that in pediat-
rics needs thorough elucidation.
As obesity and the metabolic syndrome are known to 
be related to a state of chronic low grade inflammatory 
stress, it is hypothesized that this causes a stimulatory 
response to hypothalamic adrenal axis (HPA) together 
with the sympathetic nervous system; events that create a 
state of clinically silent hypercortisolism. The latter phe-
nomenon is associated with excessive cortisol, aldoster-
one and ACTH production [1].
Mineralocorticoid receptor (MR) has high binding 
affinity for both cortisol and aldosterone [1], whereas glu-
cocorticoid receptor (GR) is selective for cortisol. Aldos-
terone promotes MR, which in turn may be followed by 
inflammation and vascular injury, ultimately leading to 
heart and renal diseases as well as stroke. Augmented 
levels of these hormones in hypertensive individuals may 
be associated with ACTH secretion which enhances the 
production of not only cortisol, but also of aldosterone 
for a short-term period. Individuals with less efficient 
cortisol synthesis maintain a subtle ACTH drive to the 
adrenal gland which may result in hyperplasia of both 
zona fasciculata and glomerulosa, causing increased syn-
thetic capacity for both cortisol and aldosterone [2].
Chronically activated HPA axis is also linked to higher 
prevalence of insulin resistance, obesity, IGT, hyperten-
sion and dyslipidemia. This metabolic derangement is due 
to activated adipocytokine release which in turn results in 
a state of low level systemic chronic inflammation induc-
ing atherosclerosis and endothelial dysfunction [3, 4].
Beta-type natriuretic peptide (BNP), a neurohor-
mone synthesized in the cardiac ventricles, is released 
as pre proBNP and then enzymatically cleaved to the 
N-terminal-proBNP (NT-proBNP) and BNP upon ven-
tricular myocyte stretch. In practice, there is increasing 
awareness to the significance of BNP in the pathophysi-
ology, diagnosis and prognosis of cardiovascular disor-
ders beyond heart failure [5]. The association of BNP to 
obesity and characteristics of the metabolic syndrome in 
adults and aged patients is well established, but that in 
pediatrics needs scrupulous elucidation. Albeit the well-
documented associations between natriuretic peptide 
levels and obesity, information on potential links with 
other metabolic risk factors and adrenal hormones are 
still contentious.
Vascular endothelial dysfunction is known to occur early 
in the atherosclerotic process and is predictive of cardio-
vascular prognosis. Cardiovascular risk factors such as 
hypertension, diabetes, hyperlipidemia, and obesity have 
been observed to be associated with vascular endothelial 
dysfunction, even prior to the development of clinically evi-
dent coronary atherosclerosis [6]. Indeed, vascular endothe-
lial dysfunction can be stimulated by inflammatory triggers 
that include free radicals and proinflammatory cytokines, 
producing adhesion molecules such as intercellular adhe-
sion molecule-1 (ICAM-1), p-selectin and vascular cell 
adhesion molecule-1 (VCAM-1), vasoactive peptides such 
as endothelin-1; generation of CRP, all of which are involved 
in the modulation of leukocyte recruitment (mediating the 
attachment and transmigration of leukocytes across the 
endothelial surface) and platelet adhesion [7]. Interestingly, 
excess glucocorticoids are reported to impair endothelium-
dependent vasodilatation in humans in vivo [8].
The aim of this study was to assess the association of 
plasma NT-pro β-type natriuretic peptide (NT-proBNP) 
levels and mediators of HPA axis; cortisol and aldoster-
one in young obese metabolic syndrome patients with 
escalating stages of hypertension; normotensive (NT), 
pre-hypertension (pre-HT) and hypertensive (HT) pedi-
atric patients. Moreover, the effects on metabolic risk 
factors, pro-inflammatory cytokines; TNF-α, IL-6 and 
IL-23, as well as vascular endothelial markers; ICAM, 
VCAM and p-selectin are addressed.
Methods
In the current non-randomized study, 60 obese patients 
were enrolled. These comprised 20 obese normotensive, 
20 prehypertensive and 20 stage 1 hypertensive young 
patients from the Pediatric Outpatient Clinic at the 
Endemic Disease Hospital at Cairo University in Egypt. 
The average age was 13–17  years, including both gen-
ders (27 males and 33 females). Group I (obese-NT) was 
composed of 20 young obese normotensive patients with 
MS (11 females and 9 males, mean age 13.8 ± 0.9 years). 
Group II (MS-pre-HT) included 20 young obese hyper-
tensive patients (11 females and 9 males, mean age 
14.7 ± 1.6 years); while Group III (MS-stage 1HT) included 
20 young obese patients diagnosed with stage 1 hyperten-
sion (11 females and 9 males, mean age 15.1 ± 1.1). Thirty 
volunteers (age and sex matched; 12 females, 18 males) 
with normal BP (<120/80 mmHg), healthy hemodynamic 
and normal biochemical parameters were recruited in our 
study as a healthy control group.
Ethics approval and consent to participate
The study protocol was approved by the local ethics com-
mittee of the Faculty of Medicine, Cairo University, and 
informed written consent was obtained from the parents 
of the patients and volunteers before entering the study.
Inclusion criteria for both groups were pediatric age 
(≤18  years) when diagnosed with obesity, described as 
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BMI > 30. The classification of the stage of hypertension 
was determined according to JNC-8 as follows;
Normal control systolic BP < 120 mmHg and diastolic 
BP: <80 mmHg.
Pre-HT systolic BP: 120–139  mmHg and/or diastolic 
BP: 80–89 mmHg.
Stage1 HT systolic BP: 140–159 mmHg and/or diastolic 
BP: 90–99 mmHg.
According to the criteria of the US National Cholesterol 
Education Program Adult Treatment panel III (2001), 
metabolic syndrome was diagnosed if at least three of the 
following elements were fulfilled including central obesity;
  • Central obesity [waist circumference ≥102 (men), 
≥88 cm (women)].
  • Dyslipidemia; elevated serum triglyceride levels 
≥1.7  mmol  l/L (150  mg/dL), reduced serum HDL-
cholesterol <40 mg/dL(men), <50 mg/dL) (women).
  • Elevated fasting plasma glucose 
≥6.1 mmol l/L(110 mg/dL).
  • Elevated blood pressure (BP, systolic BP ≥ 130 mmHg 
or diastolic BP ≥ 85 mmHg).
Exclusion criteria referred to autoimmune disease 
states, acute kidney injury or unsatisfactory vascular 
access or any other known condition that would affect 
cytokine levels. None of our patients had been treated 
with antibiotics, anti-inflammatory or corticosteroid 
medications during the study period.
Venous blood samples (2  ml) were obtained early in 
the morning after overnight fasting from all patients/
controls and were divided into two aliquots: one part was 
anticoagulated for plasma separation for NT-proBNP 
assessment. The remainder of the samples were allowed 
to clot and sera were then separated by centrifugation 
(3500 rpm, 20 min, 25 °C) and stored at −20 °C for later 
biochemical determinations. Serum levels of fasting glu-
cose, insulin and lipid profile (T-Chol, HDL-C and TG) 
were analyzed using Synchron CX5 autoanalyzer (Beck-
man, USA), while LDL-cholesterol levels were calculated 
by using the Friedewald formula.
Moreover, pro-inflammatory markers such as tumor 
necrosis factor (TNF)-α, interleukin (IL)-6 and inter-
leukin IL-23 were assessed using commercially available 
enzyme-linked immunosorbent assay kits (R&D Systems 
Inc., Minneapolis, MN, USA) according to the manu-
facturer instructions. The intra-/inter- assay coefficient 
of variation (CVs) for TNF-α is 10–12  %, and its lower 
level of detection (LOD) was 3 pg/ml, while the LOD for 
IL-6 =  1 pg/ml and IL-23 =  0.2 pg/ml. High sensitivity 
CRP was assessed using available enzyme-linked immu-
nosorbent assay kits (R&D Systems Inc., Minneapolis, 
MN, USA) according to the manufacturer instructions. 
The intra-/inter- assay coefficient of variation (CVs) for 
TNF-α is 10–12 %, and its LOD = 0.1 mg/L.
Serum levels of soluble adhesion molecules; sICAM, 
sVCAM, p-selectin were determined using commercial 
monoclonal antibody-based enzyme-linked immuno-
sorbent assay (ELISA) kits (Ray-Bio® Human, RayBiotech, 
Inc., Norcross, GA). The intra-/inter- assay coefficient of 
variation (CVs) for serum p-selectin is 10–12 %, whereas 
LOD were as follows: p- selectin  =  30  pg/ml, 
sVCAM = 0.3 ng/ml and sICAM = 23 pg/ml.
In the separated plasma portions, the level of NT-
proBNP was quantitatively assessed using commercial 
monoclonal antibody-based enzyme-linked immuno-
sorbent assay (ELISA) kits (COBAS from Roche diagnos-
tics, GmbH, Mannheim, Germany), with LOD = 5.00 pg/
ml. Aldosterone, ACTH and cortisol were measured by 
RIA technique (Invitrogen, California, USA).
Measurements were performed according to the man-
ufacturer’s instructions; each sample was measured in 
duplicate and the arithmetic mean was considered as a 
final result. Results were calculated by reference to stand-
ard curves.
Clinical assessments included complete history tak-
ing, past medical and disease history for confirming the 
appropriateness of the patients to the inclusion criteria. 
BP and BMI monitoring were according to the interna-
tional guidelines.
Statistical analysis
Continuous variables are expressed as mean ± standard 
deviation (SD) and normality was assessed by the Shap-
iro–Wilk test. Normal transformation of non-normally 
distributed data was done by Lg10 multiplication. Differ-
ences between groups were assessed by one-way analysis 
of variance (ANOVA) followed by Tukey–Kramer post 
hoc test. The association between the parameters was 
determined using the Pearson’s correlation coefficient. 
Receiver operating characteristic (ROC) curve analysis 
was used to assess the predictive ability of the assessed 
biomarkers; the area under the curve (AUC) and the con-
fidence intervals (CI) were calculated with the Wilcoxon 
and Mann–Whitney tests. All reported probability values 
were two-tailed, and a P value <0.05 was considered sta-
tistically significant. Statistical analysis was performed 
using the SPSS 20.0 statistical software package (SPSS 
Inc., Chicago, Ill., USA).
Results
Characteristics of the study participants are listed in 
Table  1; their age range was 13–17  years. Overall, 20 
young obese normotensive young patients (11 females 
and 9 males), as well as 60 young obese patients with BMI 
exceeding 30 (33 females and 27 males) were enrolled 
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in the study. According to the JNC-8 classification these 
obese patients were further subclassified according to 
their stage of blood pressure; normotensive (NT), prehy-
pertensive pre-HT and stage 1 hypertension (HT).
The increase in the assessed metabolic parameters; glu-
cose, insulin and HOMA-index has progressed in accord-
ance with the stage of blood pressure; data shown in 
Table 1. Both glucose and insulin levels in normotensive 
obese group increased significantly approximately 1.34, 
1.53 fold; respectively, compared to control group. The 
significant elevation of glucose level in the obese prehy-
pertensive and hypertensive groups reached 1.45 and 1.6 
folds, respectively from the baseline control value. More-
over, the significant increase of obese pre-HT reached 
7.7 % from the obese NT, while the extent of elevation of 
obese HT reached 10.5 % times from pre-HT and 19.1 % 
from NT; all significant at P < 0.05.
A similar pattern was obvious in the insulin level, where 
the significant elevation of insulin level in the obese pre-
hypertensive and hypertensive groups reached 1.9 and 
2.42 folds, respectively from their baseline control value. 
Moreover, the significant increase of obese pre-HT 
reached 23.9  %; from the obese NT, while the extent of 
elevation of obese HT reached 27.5  % times from pre-
HT and 58  % from NT; all significant at P  <  0.05. The 
HOMA-index doubled in the obese NT (2.21 vs 1.06), 
increased 33.4 % in the pre-HT group (2.95), and 41 % in 
the obese HT group (4.16).
Concerning the lipid profile, illustrated in Table 1, the 
significant elevation was only reported in the obese NT 
group, as the levels of TG, T-Chol and LDL-C increased 
2.6, 2.2 and 2.58 folds, respectively, compared to their 
normal control values (75.8  ±  10.37; 132.1  ±  7.16, 
77.2  ±  4.7; respectively). The tracked increase of the 
aforementioned levels in the pre-HT and HT groups 
was subtle, yet insignificant; except for T-Chol and 
LDL-C in the HT group, where their increase was sig-
nificant and reached 8 and 9.6 %, respectively, compared 
to their obese NT levels. The change of HDL-C con-
centration among the three obese groups (NT, pre-HT 
and HT) was undetectable, however they were all sig-
nificantly higher than the normal levels (1.25,1.24, 1.27 
fold, respectively).
Table  2 illustrates the progressive elevation of NT-
proBNP and the adrenal hormones levels, cortisol, 
aldosterone and ACTH from obese normotensive to 
hypertensive individuals.
Regarding cortisol level, a significant decrease (37.9 %) 
in the obese NT group was observed, which is progres-
sively elevated in both pre-HT and HT groups (1.6 and 
1.4 times, respectively). The highest level of cortisol was 
recorded in the obese HT group (12.71 ± 0.553), which 
increased 42.7 % from the pre-HT level and is 2.3 times 
the obese NT level; all significant at P < 0.05.
Aldosterone level was significantly increased in the 
obese NT group (1.5 times) compared to the control level, 
Table 1 Anthropometirc measures of obese patients with NT, pre-HT and HT and their plasma metabolic parameters (vs 
their control group)
Values are mean ± SD for control healthy, obese normotensive, prehypertensive and hypertensive patients groups
Values (*) is significantly different from control group; (#) significantly different from normotensive obese patients, (a) significantly different from prehypertensive 
obese patients
Values are statistically significant at P < 0.05 using one way ANOVA with LSD as post hoc test. (SPSS program)
Control-patients (N = 30) Obese patients
NT (N = 20) Pre-HT (N = 20) HT (N = 20)
Age (years) 14.5 ± 1.5 13.8 ± 0.9 14.7 ± 1.6 15.1 ± 1.1
Gender (M/F) 18/12 9/11 9/11 9/11
Diastolic BP (mmHg) 72. 5 ± 5.2 80.3 ± 2.1* 83.1 ± 2.5* 87.3 ± 2.6*, # a
Systolic BP (mmHg) 114 ± 6.1 117.5 ± 3.4 128.1 ± 3.9*, # 147 ± 6.5*, #, a
BMI 21.2 ± 1.2 32.9 ± 0.5* 32.2 ± 0.7* 33.6 ± 0.6*
Glucose (mg/dl) 78.2 ± 4.7 105.4 ± 3.3* 113.6 ± 1.8*, # 125.6 ± 5.3*,#, a
Insulin (µIU/ml) 5.5 ± 0.7 8.5 ± 0.4* 10.5 ± 1.5*, # 13.5 ± 0.7*, #, a
HOMA-index 1.1 ± 0.1 2.2 ± 0.03* 2.9 ± 0.06* 4.1 ± 0.09*, #, a
TG (mg/dl) 75.8 ± 10.4 198.7 ± 19.7* 206.5 ± 28.9* 215.9 ± 22.5*
TC (mg/dl) 132.1 ± 7.2 289.2 ± 16.7* 299.2 ± 30.7* 312.5 ± 21*, #
LDL-C (mg/dl) 77.2 ± 4.7 199.6 ± 12.8* 208. 5 ± 23.9* 218.9 ± 13.7*, #
HDL-C (mg/dl) 39.73 ± 3.5 49.75 ± 3.8* 49.46 ± 4.1* 50.53 ± 3.8*
Metabolic syndrome No No Yes Yes
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and is further elevated in the pre-HT group (48.3 %). The 
HT level of aldosterone was the highest (320.2 ± 22.48) 
recording 1.63 folds the pre-HT level and 2.42 times the 
obese NT level, all significant at P < 0.05.
The effect of obesity on the ACTH normal level was 
undetectable, however the highest level was traced 
in the pre-HT group, which was 3.2 fold the obese NT 
value. Interestingly, ACTH levels decreased significantly 
(55.3 %) in the obese HT group.
The NT-proBNP levels in normotensive obese group 
increased significantly, approximately 5.2 fold (P < 0.05), 
compared to control group. The significant elevation 
in the obese prehypertensive and hypertensive groups 
reached 8 and 12 folds, respectively from baseline control 
value. Moreover, the significant increase of obese pre-HT 
reached 1.5 times from the obese NT; while the extent 
of elevation of obese HT reached 1.5 times from pre-HT 
and 2.3 times from NT; all significant at P < 0.05.
The levels of the assessed proinflammatory cytokine 
markers; TNF-α, IL-6 and IL-23 as well as CRP in all 
groups are presented in Table  2. It shows significantly 
increased levels of TNF-α, IL-6 and IL-23 and CRP 
by 2.6, 4.2, 5.9 and 2.3 times, respectively (P  <  0.01), in 
obese normotensive patients, when compared with con-
trol healthy individuals group. The progressive elevation 
of inflammatory markers aligned with the stage of HT, as 
follows; the level of TNF-α in the pre-HT group was 2.4 
times the obese NT level, and increased 2.2 times in the 
HT group; the latter is 5.25 fold the NT level, all signifi-
cant at P < 0.05.
In the pre- HT group IL-6, IL-23 and CRP increased 
significantly 1.8, 1.2 and 2 fold, respectively, compared to 
the obese NT level. The levels of CRP and both cytokines; 
IL-6 and IL-23, doubled in the HT group, which reached 
3.6, 2.42 and 4.2 fold the NT level, all significant at 
P < 0.05.
The endothelial markers, ICAM, VCAM and p-selec-
tin, are illustrated in Fig. 1, showing 2.39, 4.13 and 3.58 
fold significant increases in their levels in the obese NT, 
compared to their control levels. The increase in the lev-
els of the endothelial markers among the obese groups 
was in alignment with the stage of hypertension. In the 
pre- HT group the increase in levels of ICAM, VCAM 
and p-selectin was 44.8, 43.2 and 30.5  %, respectively, 
compared with obese NT. These values were further ele-
vated in the obese HT, as 53.6, 34.6 and 26.1 %, compared 
to obese pre-HT group, and 122.6, 92.8 and 64.5 %, com-
pared to obese NT group; all respective to ICAM, VCAM 
and p-selectin levels.
Table 2 Serum adrenal hormones, endothelial, and  inflammatory markers in control, obese patients with NT, pre-HT & 
HT
Values are mean ± SD for control healthy, obese normotensive, prehypertensive and hypertensive patients groups
Values (*) is significantly different from control group; (#) significantly different from normotensive obese patients, (a) significantly different from prehypertensive 
obese patients. Values are statistically significant at P < 0.05 using one way ANOVA with LSD as post hoc test. (SPSS program)
Control-subjects (N = 30) Obese patients
NT (N = 20) Pre-HT (N = 20) HT (N = 20)
Adrenal hormones
Cortisol (µg/dL) 9.1 ± 1.4 5.6 ± 0.7* 8.9 ± 2.4*, # 12.7 ± 0.5*, #, a
Aldosterone(µg/dL) 88.6 ± 8.5 132.1 ± 6.9* 195.9 ± 70.9*, # 320.2 ± 22.4*,#, a
ACTH(pg/ml) 23.8 ± 2.9 24.8 ± 5.6 79.6 ± 42.07*, # 44.2 ± 7.5*, #, a
NT-pro BNP(pg/ml) 73.07 ± 11.05 377.3 ± 87.8* 585.7 ± 155.7*, # 881.1 ± 130.9*, # a
Cytokine markers
TNF-α (ng/ml) 2.3 ± 0.5 6.02 ± 1.4* 14.3 ± 7.6*, # 31.6 ± 6.7*, #, a
IL-6 (ng/ml) 1.2 ± 0.2 5.1 ± 1.2* 9.3 ± 4.6*, # 18.5 ± 2.4*, #, a
IL-23 (ng/ml) 16.1 ± 3.1 76.9 ± 6.3* 93.5 ± 15.5*, # 186.6 ± 23.5*, #, a








obese pre  HT











Fig. 1 Pattern of adhesion molecules in the investigated groups 
(obese NT, obese pre-HT, obese HT) vs control. Values (*) is signifi-
cantly different from control group; (#) significantly different from 
normotensive obese patients, (a) significantly different from prehyper-
tensive obese patients
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Correlational analyses between cortisol, aldosterone, 
NT-proBNP and hs-CRP with the metabolic and endothelial 
risk factors
Results of the correlational analyses relating cortisol, 
aldosterone, NT-proBNP and hs-CRP with metabolic, 
inflammatory and endothelial risk factors are shown in 
Tables  3 and 4. These markers illustrated positive and 
significant correlations (all at P  <  0.001) with systolic 
and diastolic BP, glucose, insulin, all assessed cytokines 
(TNF-α, IL-6,IL-23) and endothelial markers (ICAM, 
VCAM and p-selectin). However, NT-proBNP and hs-
CRP displayed subtle correlation with TG and TC from 
the lipid profile that was only significant at P < 0.05. NT-
pro BNP and hs-CRP were positively correlated with TG 
(r = 0.414; r = 0.301; P < 0.05), and with TC (r = 0.431; 
r = 0.298; P < 0.05). Interestingly, cortisol was only sig-
nificantly correlated with TC (r = 0.216, at P < 0.05). 
The sensitivity and specificity of the assessed factors; 
cortisol, aldosterone, NT-pro BNP, and hs-CRP in pre-
dicting hypertensive-induced cardiovascular risk was 
illustrated via the Receiver Operating curves (Fig. 2a–d). 
The ROC analysis was applied between obese NT and 
pre-HT patients and showed that there was a high sen-
sitivity and specificity for the predictive validity of aldos-
terone (92.307  % sensitivity and 91.7  % specificity; best 
cut off value >138.5 ng/dl; Fig. 2a), cortisol (92.307 % sen-
sitivity and 83.4 %, specificity, best cut off value >6.4 ng/
dl; Fig. 2b), NT-pro BNP (84.61 % sensitivity and 83.4 % 
specificity; best cut off value >445.5  pg/ml; Fig.  2c) in 
differentiating between NT group vs pre-HT metabolic 
syndrome groups. Interestingly, hs-CRP had the highest 
specificity (92.31  %), but sensitivity of 86.66  % and the 
best cut off value of >2.85 (mg/L), as shown in Fig. 2d.
Discussion
In recent years, a considerable attention has been pro-
posed on the involvement of HPA axis stimulation and 
secretion of adrenal hormones; aldosterone, cortisol in 
metabolic syndrome. Thus, data on the effects of adrenal 
hormones on myocardium, hypertension and its cardio-
vascular complications, as well as vascular endothelium, 
is being accumulated in adult population; however that in 
pediatrics remains scarce.
The current study presents a significant positive asso-
ciation of plasma aldosterone, and cortisol levels with 
obesity and elements of metabolic syndrome and their 
effect on immune-inflammatory markers according to 
the increased stage of hypertension in a pediatric cohort. 
This ensued in parallel with the escalating levels of adre-
nal hormones and NT-pro BNP levels in obese nor-
motensive, pre hypertensive and stage 1 hypertensive 
patients. The correlation of the adrenal hormones and 
NT-pro BNP with the elements of MS and their utility as 
prognostic measures is the focus of the current study.
A number of studies demonstrated a greater respon-
siveness and hyperactivity of the HPA axis to various 
stimuli in patients with abdominal obesity exhibiting 
association with attenuated negative feedback in the HPA 
axis [9]. Certain mechanisms are implied attempting to 
describe the body fat mass impact on secretion of aldos-
terone and cortisol [10]. The latter refers to the direct 
effect of cortisol due to an increase in hepatic production 
of angiotensinogen, binding MC receptor, and a rise in 
vascular reactivity. In addition, the high flux of free fatty 
Table 3 Correlations between  cortisol, aldosterone, NT-
proBNP and hs-CRP and metabolic risk factors among stud-
ied groups
Values are Pearson’s correlations using SPSS program
Cortisol Aldosterone NT-proBNP hs-CRP




































TC (mg/dl) r = 0.216
P < 0.05








HDL-C (mg/dl) NS NS NS NS
Table 4 Correlations between  cortisol, aldosterone, NT-
pro BNP and CRP on  inflammatory and endothelial mark-
ers among studied groups
Values are Pearson’s correlations using SPSS program
Cortisol Aldosterone NT-pro BNP hs-CRP























































Page 7 of 11Schaalan et al. Diabetol Metab Syndr  (2016) 8:52 
acids triggers a neuroendocrine reflex, resulting in the 
higher circulating levels of cortisol [3] notoriously linked 
to several cardiovascular dysfunctions including hyper-
tension [4]. Since both the HPA axis and the sympathetic-
adrenomedullary system are activated by psychological 
stress, aldosterone may be released due to psychological 
stress, that is reported to coincide with obesity states, 
providing an additional link between negative affective 
states and cardiovascular health. Early studies on stress 
characterized pathological consequences of excess min-
eralocorticoid activity referring to high blood pressure 
and evidence of myocardial fibrosis and necrosis [10].
AT-1 receptors mediate angiotensin-II induced stimu-
lation of aldosterone release which is reported to be 
attributed to metabolic distortions associated to insulin 
resistance, including hyperglycemia, dyslipidemia and 
hypertension; events that are caused by acceleration of 
the atherosclerotic process and endothelial dysfunc-
tion [11]. This explains the current increase of aldoster-
one levels in the different obese groups, associated with 
the increased extent of hypertension and rationalizes 
the current positive correlation of aldosterone with glu-
cose, insulin and HOMA-index, and currently assessed 
endothelial markers, ICAM, VCAM and p-selectin. 
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Fig. 2 ROC curves panel of aldosterone, cortisol, NT-pro BNP and hs-CRP; a illustrates ROC of aldosterone; b illustrates ROC of cortisol; c illustrates 
ROC of NT-pro BNP, and d illustrates ROC of hs-CRP
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Interestingly, no significant association was reported 
between aldosterone and all parameters of lipid panel.
With regard to the reported increase in HOMA-index, 
the surrogate marker of insulin resistance, studies in 
humans have shown that obesity is attributed to aldos-
terone increased production is correlated with increased 
insulin resistance, nonaligned with body mass index [12]. 
The findings above coincide with our results. Moreover, 
an elevated mineralocorticoid activity is reported to be 
one of the hypertension inducing mechanisms accounted 
for obesity [13].
Moreover, according to the pre-clinical studies, aldos-
terone induces the expression of the transcription factor, 
nuclear factor-kappa B (NF-κB) and genes responsible for 
inflammation, fibrosis, and atherosclerosis [14]. While 
experimental studies reported the reduction of athero-
sclerosis upon MR blockade [15], other clinical studies 
revealed that aldosterone infusion raised circulating IL-6 
levels in contrast to spironolactone, which blocked IL-6 
accompanied with administration of angiotensin II [16]. 
These evidences explain the current association of hyper-
aldosteronism and CRP, adipocytokine release of TNF-
α, IL-6 & IL-23 as well as adhesion endothelial markers; 
ICAM and VCAM and p-selectin.
Based on the similarities between cortisol and aldoster-
one in response to HPA axis activation, it is assumed that 
some inducing factors engaged in dysregulation of both 
aldosterone and cortisol.
The current findings reported a significant decrease in 
cortisol in NT-obese group, compared to their control 
counterparts. However, with further elevation in BP in 
pre-HT and stage 1 HT groups cortisol was accordingly 
elevated.
Several studies have been conducted here and else-
where investigating the link between cortisol and obesity; 
yet, the correlation between obesity and cortisol levels 
exhibits contradicting results and remains a subject of 
debate.
Indeed, low circulating cortisol concentrations have 
been measured in obese individuals where enhanced 
excretion of urinary free cortisol was found in those with 
MS [17], which assumingly may be referred to increased 
peripheral metabolism of cortisol. Contrariwise, a study 
that investigated the impact of cortisol on both body fat 
distribution and total fat in obese females did not support 
the previous finding [18]. As a matter of interest, corti-
sol clearance is likely to correlate negatively with insulin 
sensitivity, where such a correlation does not depend on 
body fat [19]. There are also numerous studies suggest-
ing that glucocorticoids affect the differentiation and pro-
liferation of human adipocytes with more receptors in 
visceral than in sc adipose tissue. In addition, glucocor-
ticoids are reported to relocate adiposity from peripheral 
to central depots, increase the size and number of fat 
cells, and promote lipolysis with the release of free fatty 
acids into the circulation [20]. Another study also dem-
onstrated the positive relation of excessive cortisol secre-
tion to high intraabdominal fat distribution [21].
Being evident in about 80  % of adult patients and in 
almost 50  % in pediatrics and adolescent individuals, 
hypertension is one of the most significant factors of 
hypercortisolism. A lot of documented data suggested a 
link between cortisol and systolic and diastolic BP lev-
els [18, 21]. This correlation is assumingly related to the 
impact of stress associated with the activation of the HPA 
axis and sympathetic nervous system. The above is pre-
determined by the fact that patients with MS and hyper-
tension are reported to have more elevated urine levels of 
both cortisol and catecholamine metabolites in contrast 
to healthy individuals [22]. An increased responsiveness 
to vasoconstrictors, viz. ET-1, together with a reduced 
vasodilator production viz. NO is likely to be another 
mechanism by which glucocorticoids enhance BP. In 
addition, the endothelin system is activated in hyper-
cortisolism, resulting in elevated plasma ET-1 levels that 
may take part in the pathogenesis of early atheroscle-
rosis in such a disorder [23]. MS, hyperinsulinemia and 
insulin resistance are suggested to trigger ET-1 release 
which later on promotes renal injury and creates another 
pathway to hypertension [24]. No change or a slight rise 
in BP in normal subjects is observed as insulin exerts 
both; pressor (via enhanced sympathetic neural flow) and 
depressor (through vasodilatation) effects. On the other 
hand, in insulin resistance-hyperinsulinemia state, an 
imbalance between these two effects occurs [25].
These findings coincide partly with our results, as the 
current hypercortisolism in both obese pre-HT and HT 
groups is associated with concomitant derangements of 
glucose and insulin homeostasis, but failed to associate 
with any of the assessed lipid panel parameters. This is 
further confirmed by the significant positive correlation 
between cortisol and both glucose and insulin levels and 
the subtle, insignificant correlations with all parameters 
of the lipid profile. The latter finding contradicts with 
previous studies that found hypertriglyceridemia and low 
HDL-C were associated with increased cortisol, in both 
hypercortisolism and metabolic syndrome [26, 27]. The 
latter studies reported an association of hypercortisolism 
with elevated fasting blood glucose levels, especially 
with patients with metabolic syndrome. The correlation 
between fasting hyperglycemia and cortisol is caused by 
the glucocorticoid outcomes on hepatic gluconeogenesis 
and insulin secretion.
In the current study, an increased serum overnight 
cortisol level is likewise linked to insulin resistance, 
which in its turn is assessed against homeostasis model 
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assessment. Thus, the following finding complies with 
in  vivo  and  in vitro  data proving that glucocorticoids 
regulate insulin secretion while higher cortisol concen-
trations are attributed to a reduced insulin secretion. 
Besides, a study conducted in obese children with- or 
without insulin resistance (homeostasis model assess-
ment >4 or ≤4, respectively) demonstrated that body 
weight reduction contributed to lowering both corti-
sol levels and insulin resistance in the insulin-resistant 
group. However, children without insulin resistance did 
not manifest the same results [28].
In our study, obese subjects with higher BP displayed 
higher NT-pro BNP levels than non-obese individu-
als, which may have an impact on their susceptibility to 
hypertension and consequent cardiovascular disorders 
[29, 30]. Controversial findings on the levels of BNPs 
in several cardiac settings are reported in the litera-
ture. Unlike the findings of Mehra et  al. [31] reporting 
decreased BNP in obese individuals with heart failure, 
our obese patients revealed higher NT-proBNP concen-
trations which are further increased with elevations in 
blood pressure. Our findings align with the results from 
another study which reported equivalent concentrations 
of increased A-type natriuretic peptide and BNP in obese 
normo- pre-hypertensive and hypertensive individuals 
[32].
Previous studies, on White, Asian and African Ameri-
can populations, have demonstrated an eloquent trans-
posed relation between BNP levels and both prevalent 
metabolic syndrome and individual components of meta-
bolic syndrome (obesity in specific) [33].
Moreover, BNP has been hypothesized to affect lipid 
and glucose metabolism through more direct pathways, 
as it may raise insulin levels, as well as glucagon secre-
tion, instigating both lipolysis and release of triacylglyc-
erols from adipose tissue [33].
A variety of factors other than myocardial stretch have 
been shown to stimulate secretion of BNP, such as myo-
cardial ischemia, endocrine and paracrine factors such 
as endothelin, angiotensin II, and TNF-α. In the latest 
report on type 1 diabetes, TNF-α was postulated as a 
key molecule for the elevation of BNP and was demon-
strated to be a key player in the development of diabetic 
complications [34]. These findings agree with the current 
positive correlation of NT-pro BNP and TNF-α. Moreo-
ver, the current data are confirmatory to the findings of 
Beygui et  al. [35] for patients with high pro BNP levels 
showing higher cortisol and aldosterone levels.
These findings provide evidence that the addition of 
aldosterone and cortisol measurements could be used 
as an adjunct to NT-proBNP levels to define a subgroup 
of patients with very high risk of coronary heart disease. 
Moreover, the ROC analyses performed in the current 
study showed that there was a high sensitivity and speci-
ficity for the predictive validity of cortisol (100 % sensitiv-
ity and 92.31 % specificity), aldosterone (100 % sensitivity 
and 92.32  % specificity), NT-proBNP (100  % sensitivity 
and 92.308 % specificity) in differentiating between pre-
HT group vs HT metabolic syndrome groups.
Concerning our secondary aim to assess the endothe-
lial functions and their surrogate markers of immune-
inflammatory endpoints in the tested groups, we found 
that metabolic syndrome in pediatrics is characterized 
by a low grade inflammatory state and is associated with 
an increase in immune-inflammatory mediators; hs-CRP 
and cytokines; TNF-α, IL-6 and IL-23, markers that are 
progressively elevated with increased stage of hyperten-
sion. These findings correspond with elevations of adre-
nal hormones; cortisol and aldosterone. However, only 
TNF-α and CRP showed a positive, significant correla-
tion with TG,TC and LDL-C, while IL-6 and IL-23 failed 
to achieve significance.
In response to this elevated plasma level of the inflam-
matory cascade and LDL oxidation, a concomitant flux 
of adhesion factors; ICAM, VCAM and p-selectin are 
released by endothelial cells and are theorized to corre-
late with impaired vascular reactivity. Furthermore, the 
correlation analysis revealed significant positive correla-
tion between endothelial markers; ICAM, VCAM and 
p-selectin; and each of systolic and diastolic BP, HOMA-
index, all lipid profile except HDL-C and proinflamma-
tory cytokines; TNF-α, IL-6, IL-23 and hsCRP.
Moreover, as explained in a study of Taddei et  al. 
[36] on hypertensive patients’ offspring, such display of 
endothelial dysfunction is not only linked to cardiovascu-
lar disease but may also precede its development. Hence, 
although the study subjects were normotensive, they 
exhibited endothelial dysfunction. Interestingly, another 
study reported appearance of endothelial dysfunction in 
symptom-free children and young adults at high risk for 
atherosclerosis [37]. The contributing pathophysiologic 
mechanism include low NO bioavailability, upregulating 
VCAM-1 in the endothelial cell layer by inducing NF-κB 
expression [38], TNF-α, CRP, oxidized LDL and its recep-
tor-1 (LOX-1). The expression of VCAM-1, ICAM-1, 
and p-selectin plays a role in triggering the inflamma-
tory process and has been indicated as a possible link of 
a low-grade chronic inflammatory process to atheroscle-
rosis and  various endocrine disorders. VCAM-1 binds 
monocytes and T lymphocytes, which is the first stage of 
inflammatory cells invasion in the vessel wall [39].
In another study of Prazny et  al. [40], increased 
ICAM-1 concentration was reported in patients with 
hypercortisolism, reflecting the induced endothelial 
dysfunction. It was shown that ICAM-1 was consid-
erably higher in patients with increased cholesterol 
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levels compared to those with increased BMI. The control 
group displayed higher ICAM-1 concentration in sub-
jects with higher BMI. Besides, in the control subjects, 
ICAM-1 and p-selectin levels were strongly correlated 
with triglycerides. The findings above also demonstrate 
the link between endothelial dysfunction, obesity and 
lipid metabolism parameters under normal conditions. 
These findings are in alignment with ours, as VCAM is 
only endothelial marker that failed to correlate with our 
assessed lipid profile.
To this end and due to the key role aldosterone and 
cortisol play, both deserve consideration to be included 
as the primary screening target in metabolic syndrome 
patients, and earlier in patients with pre-HT and stage 1 
HT patients for preventing CV complications. Moreover, 
the integration of these markers may increase the prog-
nostic and diagnostic sensitivity and specificity and used 
for the risk stratification of metabolic syndrome patients 
and hopefully  would  aid in the prevention of develop-
ment of cardiovascular diseases. However, the fact that 
this study is conducted in pediatrics limits the applica-
tion of the results to pediatrics only. Further studies on 
adult cohorts are warranted to confirm its applicability 
on the adult population.
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